PT - JOURNAL ARTICLE AU - Garon, Julie AU - Patel, Manish TI - The polio endgame: rationale behind the change in immunisation AID - 10.1136/archdischild-2016-311171 DP - 2017 Apr 01 TA - Archives of Disease in Childhood PG - 362--365 VI - 102 IP - 4 4099 - http://adc.bmj.com/content/102/4/362.short 4100 - http://adc.bmj.com/content/102/4/362.full SO - Arch Dis Child2017 Apr 01; 102 AB - The decades long effort to eradicate polio is nearing the final stages and oral polio vaccine (OPV) is much to thank for this success. As cases of wild poliovirus continue to dwindle, cases of paralysis associated with OPV itself have become a concern. As type-2 poliovirus (one of three) has been certified eradicated and a large proportion of OPV-related paralysis is caused by the type-2 component of OPV, the World Health Assembly endorsed the phased withdrawal of OPV and the introduction of inactivated polio vaccine (IPV) into routine immunisation schedules as a crucial step in the polio endgame plan. The rapid pace of IPV scale-up and uptake required adequate supply, planning, advocacy, training and operational readiness. Similarly, the synchronised switch from trivalent OPV (all three types) to bivalent OPV (types 1 and 3) involved an unprecedented level of global coordination and country commitment. The important shift in vaccination policy seen through global IPV introduction and OPV withdrawal represents an historical milestone reached in the polio eradication effort.